Bell Lab

Contact Information

John Bell, PhD
613 737-7700 70333
jbell@ohri.ca

501 Smyth Road, Box 926
Ottawa, ON K1H 8L6

What We Do

Selected Publications

Brian D. Lichty, Caroline J. Breitbach, David F. Stojdl, & John C. Bell. Going viral with cancer immunotherapy. Nature Reviews Cancer. 2014 03 July.

Fabrice Le Bœuf*, Cory Batenchuk*, Markus Vähä-Koskela, Sophie Breton, Dominic Roy, Chantal Lemay, Julie Cox, Hesham Abdelbary, Theresa Falls, Girija Waghray, Harold Atkins, David Stojdl, Jean-Simon Diallo, Mads Kaern, John Bell. Model-based Rational Design of an Oncolytic Virus with Improved Therapeutics Potential. Nature Communications 2013 Jun 14;4:1974.

Heo, J.,Reid, T., Ruo, L., Breitbach, C.,Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Kim, C.W., Burke, J.,Lencioni, R., Hickman, T., Moon, A., Lee, Y.S., Kim, M.K., Daneshmand, M., Dubois, K., Longpre, L., Ngo, M., Rooney, C., Bell, J.C.,Rhee,B-G., Patt, R., Hwang, T-H., Kirn, D.H., (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX 594 in liver cancer. Nat Med. 2013 Mar;19(3):329-36.

Russell SJ, Peng KW, Bell JC.Oncolytic virotherapy.(2012) Nature Biotechnology 30:658-70.

CJ Breitbach, J Burke, D Jonker, J Stephenson, AR Haas, LQM Chow, J Nieva, TH Hwang, A Moon, R Patt, A Pelusio, F LeBoeuf, J Burns, L Evgin, N De Silva, S Cvancic, T Robertson, JE Je, YS Lee, K Parato, JS Diallo, AFenster, M Daneshmand, JC Bell and DH Kirn. (2011)Intravenous delivery of a cancer-targeted poxvirus results in tumour-specific replication, transgene expression and efficacy in cancer patients.Nature477: 99–102.

Meet the Bell Lab